Skip to main content

What Texas can learn from Israel: Takeaways from the Texas-Israel Alliance Healthcare & Life Sciences Innovation Conference

This past Friday (Oct. 25, 2019) the Texas-Israel Alliance held its Healthcare & Life Sciences Innovation Conference, which was conveniently hosted by UT Southwestern Medical Center, where I work. The event presented 5~6 panel discussions and fireside chats that featured speakers from a wide variety of institutions and business entities including the FDA, Microsoft, Rabin Medical Center, NASA, Start-up Nation Central, several venture capital firms, and others. All of the featured talks were of uniformly high quality, but one stood out for me in terms of 1) delivering insights into what makes the Israeli innovation ecosystem unique, and 2) providing lessons that can be derived from those insights that may be useful for further developing Texas's own ecosystem. This was the fireside chat between Guy Hilton, General Manager of Start-up Nation Central, and Dr. Claire Aldridge, Associate Vice President of Commercialization and Business Development at UT Southwestern (who, in the interest of disclosure, is my boss's boss).

Below are the highlights I took away from this conversation, which primarily consisted of Guy's responses to questions posed by Claire.

Q:  Because VCs tend to prefer investing in companies that are in their own backyard, Texas-based companies have historically had difficulty attracting funding from coastal VCs (or, on the flip side, when new ventures are established on the basis of technological breakthroughs created within Texas, they often end up establishing their operations within coastal hubs rather than within Texas). What's the secret behind Israeli companies' success in attracting funding from US-based VCs?

A:  A variety of factors have been responsible:
1. The Israeli government set up an initiative during the '90s (Yozma:  link, link, link) that provided matching funds to Israeli startups that received investment funding from overseas VC firms, which helped prime the pump for further investments.
2. The fact that so many Fortune 500 companies have operations within Israel helps lower the perceived risk of investing in Israel (in addition to providing opportunities for the corporate VC arms of those companies to seek out investment opportunities within Israel).
3. Israel has developed a reputation as being a place with a high concentration of serious serial entrepreneurs.
4. The success stories of Israeli startups have been used to actively cultivate Israel's brand as a center of entrepreneurship, both by the Israeli government as well as by non-governmental organizations such as Start-up Nation Central.

Q:  Scientific research is very robust and well-funded here in Texas, but how can the state best cultivate the management talent that is needed to run the companies that will be built around those technologies that arise from the basic research? Also, how can Texas best ensure it is developing a sufficient workforce with hands-on technical experience in working in GLP/GMP environments to meet expected future needs?

A:  Israel is facing similar challenges, in that its traditional education pipeline consisting of army service followed by university education is not expected to be sufficient to create a large enough trained workforce to meet the country's future needs for talent. Guy said that the Israeli government (as well as his organization) is taking active steps to cultivate talent within sectors of the Israeli population that have traditionally been neglected, e.g., its Arab and Haredi (i.e., Jewish ultra-orthodox) communities. Start-up Nation Central has been active in organizing community-building events directed to tech workforce promotion and training within both Arab and Haredi communities within Israel.

Other interesting points arose over the course of Guy and Claire's conversation:

Digital health as an important and robust component of Israeli healthcare innovation:
  • Amazingly, Israel has ~25 years of nationwide electronic health record (EHR) data, collected by all of the four major Israeli HMOs (which collectively cover almost all Israeli citizens). These data can be made available to researchers and tech innovators in a de-identified matter, even to entities outside of Israel (more information available in this recent Forbes article here).
  • Last year, the Israeli government announced a 1 billion shekel effort to fully mine this dataset to discover new advances in preventive medicine and personal medicine (link, link, link).

Aspects of the Israeli entrepreneurial ecosystem that may be surprising to those in the US:
  • Israeli startups can be surprisingly open about sharing useful knowhow with each other, even with their competitors, e.g., regulatory knowledge, how to penetrate specific markets within the US, etc.
  • Extreme flexibility can be found among Israeli serial entrepreneurs in the form of moving into very different fields as they progress. As an example, one might find an Israeli entrepreneur who got his start working in military intelligence during his army service who then moved into cybersecurity, and then into Agtech, and then into healthcare. In contrast, serial entrepreneurs in the US are much more likely to be pigeonholed into specific industry sectors, i.e., they are far less likely to successfully raise money if their new venture is within a field that is far removed from their previous effort(s). This unique flexibility adds to the robustness of the Israeli innovation ecosystem by promoting the efficient dissemination of useful knowledge, practices, and culture between disparate sectors. 

- Isamu Hartman






Comments

Popular posts from this blog

Comics About Patents (A Work In Progress)

Back in January and February of 2018, I spent some time creating two four-panel comics about the process of 1) obtaining patent protection, and 2) monetizing those patent rights by licensing them. I drew the comics to serve as an illustration of concepts that I often find myself explaining to others in the course of my work. I've already shared these comics through  Twitter  and  Facebook  (click on either of link to see more of the creative process!). However, I thought I'd share them with my blog's readership as well. Please enjoy! I'm really hoping to reignite this project at some point in the future and create more episodes. (Click on the images below to enlarge) Episode 1: Episode 2: - Isamu Hartman

The Big Fish: Texas-Based Biomedical Companies listed on NYSE and NASDAQ

[Monday, 22 April 2013:  I added Hanger Inc. (HGR, NYSE), an Austin-based prosthetics and orthotics company I had originally missed, to the list] [Thursday, 02 May 2013:  fixed the location of Hanger Inc. (HGR, NYSE) - changed from Dallas to Austin] I have another few posts coming up on Texas-based awardees of the SBIR program. But first, a quick digression. +Levi Shapiro  asked me the following question during a phone conversation we had earlier today:  who are the "Big Players" in the Texas biomedical industry that are listed in the major stock exchanges? I knew about Luminex (LMNX, NASDAQ) off the top of my head. Other than that, though, I really had no idea. Following the advice of +Lauren Nise  , I used LexisNexis (courtesy of the UT Dallas Eugene McDermott Library ) to generate a list of publicly traded biomedical companies headquartered in Texas that are listed in either NYSE or NASDAQ. Here are the companies I found: (Open spreadsheet as a se...

Corporate Venture Capital at the Top 10 Pharma/Biotech Companies

Today I'm taking a step outside of Texas and looking at the world. Many large pharmaceutical and biotech firms maintain venture capital operations through which they invest in early-stage biomedical companies. I wanted to get a sense of what these biopharma corporate venture capital (CVC) funds are up to. Which companies have CVC funds? How active are they? What are their goals? What are they investing in? Background: general and sector-specific trends in venture capital In 2014 venture capital funding in the U.S. hit its highest annual mark since 2001, as investors participated in $47.3 billion across 3,617 deals . Within this trend Life Sciences was the second largest sector (behind only the Media and Entertainment sector) for 2014 in dollar terms with $8.6 billion invested in 789 deals, the highest level since 2007 . Corporate venture funding has followed similar trends:  2014 marked the strongest year for CVC activity since 2000 with $5.4 billion invested in U.S.-based co...